PDCD1 and neoplasm: PD‐1/PD‐L1 based immune checkpoint inhibitors can block the PD‐1/PD‐L1 pathway, reactivate tumor‐specific cytotoxic T lymphocytes in the tumor microenvironment, and restore anti‐tumor immune activity.17